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Sex differences in cardiovascular disease and cardiac physiology have been reported in humans as well as in animal
models. Premenopausal women have reduced cardiovascular disease compared to men, but the incidence of
cardiovascular disease in women increases following menopause. Sex differences in cardiomyocytes likely
contribute to the differences in male–female physiology and response to disease. Sex differences in the heart have
been noted in electrophysiology, contractility, signaling, metabolism, and cardioprotection. These differences appear
to be due, at least in part, to differences in gene and protein expression as well as in posttranslational protein
modifications. This review will focus primarily on estrogen-mediated male–female differences in protein expression
and signaling pathways in the heart and cardiac cells. It should be emphasized that these basic differences are not
intrinsically beneficial or detrimental per se; the difference can be good or bad depending on the context and
circumstances.
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Introduction
Male–female differences in cardiovascular disease (CVD)
are well documented. There are also sex differences in car-
diac myocytes, and these differences likely contribute to
the differences in male–female response to physiology and
disease. The sex differences in mRNA/protein expression
are thought to be due to differences in sex hormones, but
differences due to having two X chromosomes versus an
X and a Y chromosome [1] and epigenetic differences
should also be considered. Although testosterone can
clearly alter gene expression and contribute to sex differ-
ences, for simplicity, this review will focus on female sex
hormones and primarily on the effects of estrogen. Even
with limiting the discussion to the effect of estrogen, the
mechanism(s) by which estrogen can regulate gene ex-
pression, protein levels, and posttranslational modifica-
tions (PTMs) is very complex. This review will focus
primarily on estrogen-mediated male–female differences
in protein expression and signaling pathways in cardiac
cells.* Correspondence: murphy1@mail.nih.gov
1Laboratory of Cardiac Physiology, Systems Biology Center, NHLBI, NIH,
Bethesda, MD 20824-0105, USA
Full list of author information is available at the end of the article
© 2014 Murphy and Steenbergen; licensee Bio
the Creative Commons Attribution License (ht
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.Estrogen regulation of mRNA and protein levels
How does estrogen regulate gene expression?
Estrogen can bind to classic estrogen receptors (ER),
ERα and ERβ, which act as ligand-gated transcription
factors that bind to DNA with the help of co-activators
and co-repressors and alter DNA transcription (see [2]
for more details). Some genes appear to have an estrogen
response element (e.g., LPL [3]). Other genes such as
endothelial nitric oxide synthase (eNOS) can be regulated
indirectly by a sex-dependent microRNA (miRNA) cas-
cade [4]. Estrogen can also alter cardiac gene expression
indirectly. Estrogen-mediated changes in another organ
could, via secreted factors or other similar mechanisms,
lead to changes in cardiac tissue. The dosage of the X and
Y chromosomes can also alter gene expression [1].Estrogen can also activate rapid signaling pathways that
can alter gene expression
Estrogen can bind to estrogen receptors at the plasma
membrane and activate signaling pathways. ERα has
been shown to be associated with the plasma membrane,
and binding of estrogen leads to activation of PI3-kinase
signaling. Palmitoylation of the ER is proposed to
localize it to the plasma membrane. A splice variant of
ERα has also been suggested to be responsible for rapidMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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protein-coupled receptor (GPR30 also known as GPER)
has also been shown to bind estrogen, which leads to acti-
vation of signaling pathways such as PI3-kinase and ERK
[6,7]. Activation of plasma membrane receptors and the
resultant activation of rapid signaling pathways can also
alter gene expression, either by ligand-independent ER
activation of gene expression secondary to phosphoryl-
ation of the ER or altering levels of co-activators and
co-repressors or by activating ER-independent signals that
alter gene expression.
Estrogen regulates mRNA and miRNA expression
Estrogen alteration of cell function can occur by its
well-described action in altering transcription and in
turn protein levels. Estrogen has been shown to regulate
the expression of a large number of genes in the heart and
cardiac cells. In general, two approaches are used to evalu-
ate estrogen-regulated genes: a candidate approach and
non-biased gene profiling approach. A candidate approach
has been used to demonstrate estrogen regulation of ex-
pression of a number of genes including PGC-1α [8], con-
nexin 43 (Cx43) [9,10], adenine nucleotide translocator
[11], heat shock proteins [12], and an inhibitor of calcine-
urin (MC1P1) [13]. Several studies have used a gene pro-
filing approach and a few are mentioned to illustrate the
approach. Gaborit examined the profile of 79 ion channel
and transporter genes from non-failing male and female
human hearts and found that female hearts exhibited de-
creased expression of several K+ channel subunits, as well
as a decrease in Cx43 and phospholamban [14]. Ambrosi
et al. also examined sex differences in genes involved in
electrophysiology in the left atria and ventricles from
failing and non-failing human hearts [15]. They found sex
differences in ion channels in the left atria of failing hearts,
but no sex differences were observed in the left ventricle.
The authors suggest that the difference with the study of
Gaborit et al. could be due in part to the age of the human
donors. Studies have also examined changes in mRNA in
ovariectomized (OVX) females with and without estrogen.
Otsuki et al. [16] analyzed gene expression in the heart
comparing OVX females with and without estrogen. They
reported an increase in expression of seven genes and
decreased expression of nine genes. It is difficult to draw
conclusions from the list of genes that are regulated by
estrogen. The genes regulated are likely to depend on the
context of the cell, and thus, these estrogen-regulated
genes may vary with disease, age, and sex. Indeed, estro-
gen has been shown to differentially regulate gene expres-
sion in males versus females.
Recent data have shown that estrogen can also regulate
miRNA and that sex differences in miRNA can contribute
to sex differences in mRNA levels. There are a number of
studies showing estrogen regulation of miRNA in non-cardiac cells [17-19]. There are also a number of very
recent studies showing a role for miRNA in the heart.
A recent study has shown sexual dimorphic expres-
sion of a miRNA network in the healthy and hyper-
trophied heart [20]. They further showed that these
effects are mediated by ERβ. miR-151 has been shown
to be involved in susceptibility to arrhythmogenesis
during myocardial infarction with estrogen deprivation
[21]. Zhao et al. [22] showed that estrogen alters expres-
sion of miRNAs in the mouse aorta. They further showed
that ERα mediates upregulation of miR-203 and that miR-
203 is involved in vascular proliferation. miR-222 has
been shown to be downregulated in female hearts and
to play a role in regulation of nitric oxide synthase. These
data support the concept that sex- and estrogen-dependent
regulation of gene expression can be mediated, at least
in part, by miRNA. This is an exciting area for future
studies.
ERα and ERβ regulate expression of different genes and can
regulate genes in opposite directions
Several studies have examined gene expression changes
related to either ERα or ERβ. ERα and ERβ regulate dif-
ferent genes [23,24]. For example, using OVX mice lack-
ing either ERα or ERβ which were treated with estrogen
for 1 week, O'Lone et al. showed that ERα and ERβ
regulate different genes in the mouse aorta [25].
ERα and ERβ can also regulate gene expression in
opposite directions [26-28]. It has been proposed that ERα
and ERβ can counterbalance gene regulation in a yin/yang
manner [26], for example, ERβ can repress genes that are
upregulated by ERα and vice versa. Consistent with this
concept, ERα increases Glut4 levels in the muscle, whereas
ERβ suppresses Glut4 expression [27]. In breast cancer, an
increase in ERα is thought to increase tumor cell prolifera-
tion while an increase in ERβ is thought to reduce it. ERβ
increases while ERα decreases levels of iNOS in vascular
smooth muscle cells [28]. Thus, the effect of estrogen on
gene expression can vary depending on the relative propor-
tion of ERα and ERβ.
The effect of estrogen can vary depending on the presence
of co-activator and co-repressors
The differences in gene regulation between ERα and
ERβ are usually attributed to differences in the binding
of co-activators and co-repressors. Interestingly, estro-
gen treatment of male and female cardiac tissue can lead
to opposite effects on gene expression, which is also
attributed to difference in the availability of co-activators
and co-repressors between male and female cardiomyo-
cytes [29,30]. For example, estrogen increases the pro-
gesterone receptor in females and decreases it in males
[31]. Similarly, estrogen increases the myosin regulatory
light chain in males and decreases it in females [30].
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estrogen receptor co-activators or repressors in cardiac
cells with myocardial infarction or caloric restriction, it
is plausible that changes would occur. Furthermore, ER
can activate transcription by interaction with transcrip-
tion factors [2] such as AP1 [32], which have been re-
ported to be altered in hypertrophy [33]. Thus, it is not
surprising that there are sex differences in the changes
in gene expression following myocardial infarction [34]
and caloric restriction [35] in males versus females.
Protein and posttranslational modifications differ in males
and females
In addition to altering mRNA levels, estrogen can acti-
vate signaling pathways [7,36] that alter protein PTMs
[37,38], which can lead to additional estrogen-dependent
changes in cardiac function. Lagranha et al. [37] exam-
ined proteomic differences in mitochondria from male
versus female rats and found differences in phosphoryl-
ation of several proteins. Females had an increase in
phosphorylation and activity of aldehyde dehydrogen-
ase 2, an enzyme which has been shown to be cardio-
protective. Females also had higher levels of phosphorylation
of pyruvate dehydrogenase and alpha-ketoglutarate de-
hydrogenase than males. This increase in phosphorylation
in females would be consistent with an estrogen-mediated
increase in the PI3-kinase signaling pathway. Vatner and
co-workers [39] also examined proteomic difference in
monkey hearts as a function of age and sex. They found a
decrease in levels of several metabolic enzymes in the aged
male hearts, which they attributed to differences in ROS
production in aged males versus females. McKee et al.
examined the potential mechanism for the sex difference
in progression of hypertrophic cardiomyopathy. They
reported sex differences in cTnI phosphorylation [38]. Sex
differences in posttranslational modifications of contract-
ile proteins would be consistent with estrogen-mediated
signaling pathways. These posttranslational modifications
of contractile proteins could contribute to sex differences
in excitation-contraction coupling.
Differences in S-nitrosylation (SNO), a protein modifi-
cation that involves the addition of an NO moiety to pro-
tein sulfhydryl groups, have also been described [40,41].
An increase in NOS has been reported in females, and this
increase in NOS would be consistent with an increase in
the NO-dependent PTM and SNO. An increase in protein
SNO has been reported in hearts from female mice, and
this increase in SNO is suggested to play a role in the
reduced ischemia-reperfusion (I/R) injury in females, as
inhibition of NOS with an inhibitor such as L-NAME
blocks both cardioprotection and the increase in SNO in
females [40,41].
Taken together, estrogen, by activation of nuclear re-
ceptors or by activation of rapid signaling pathways, canlead to changes in gene expression. These effects can be
additive if the activation of nuclear receptors increases
the expression of a signaling protein such as NOS or a
kinase which can be activated by a rapid signaling path-
way that is activated by estrogen. The next section will
give a few examples of how these changes in gene
expression and signaling can lead to sex differences in
cardiac function.
Estrogen regulation of function
Calcium handling and electrophysiology
There are a number of documented sex differences in
electrophysiology [42]. Women have a longer QT inter-
val. The basis for this difference in QT interval is still
somewhat debated, but estrogen has been shown to alter
the levels of several ion channels that modulate QT inter-
val. Sex differences in gene expression of several in-
wardly rectifying K+ channels have been reported [43-45].
Kv4.3 and Kv1.5 expression are regulated by estrogen [46].
Roden and co-workers have also shown sex differences
in the late Na+ channels [47]. Sims et al. report that
the long QT in women is due to an ERα-mediated in-
crease in the L-type Ca2+ channel [48]. Iacobas et al. have
analyzed the sex-dependent regulation of the gene net-
work that regulates heart rhythm [49]. As mentioned pre-
viously, Ambrosi et al. have reported sex differences in
genes involved in electrophysiology [15], and Gaborit
has analyzed human tissue and found sex differences
in several ion channels [14]. Gaborit et al. observed a
sex-dependent isoform switch in the Na+/K+ ATPase;
they found an increase in the α1 subunit in females and a
decrease in the α3 subunit. Interestingly, Imahashi et al.
have reported sex differences in Na+ levels during ischemia-
reperfusion [50]. They found less of a rise in Na+ during
ischemia in female hearts compared to male hearts. This
sex difference in the rise in Na+ was increased if hearts
were treated with isoproterenol prior to ischemia. Male–
female differences in Ca2+ have also been observed. Treat-
ment with isoproterenol causes less of an increase in the
Ca2+ transient [51,52] and less of an increase in SR Ca in
females compared to males [52].
Sex differences in contractile proteins have also been re-
ported. Patrizio et al. [53] have shown that estrogen regu-
lates expression of the β-myosin heavy chain. McKee et al.
have shown sex differences in myofilament function and
in phosphorylation of TnI in mice with hypertrophic
cardiomyopathy [38].
Metabolic differences
Sex differences in metabolism have been reported in
humans as well as in animal models. Estrogen has been
shown to increase insulin-stimulated glucose uptake in
skeletal muscle [54], and ERα has been shown to be
required for glucose uptake in the heart [55]. There are
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[56]. These effects of estrogen on metabolism are con-
sistent with the Women's Health Initiative (WHI) find-
ing that hormone replacement therapy (HRT) resulted
in an improvement in insulin sensitivity [57]. Clegg et al.
have reported sex differences in energy homeostasis
[58]. Lewandowski's group [35] has shown male–female
differences in triglyceride level following caloric restric-
tion [35,59]. Lyons et al. have shown sex differences in
response to diabetes [60]. Using PET, Peterson has found
that women have increased fatty acid metabolism com-
pared to men. In contrast, Gabel has used 13C NMR and
isopotomer analysis and found that compared to those
from male mice, hearts from female mice have an in-
crease in the ratio of carbohydrate metabolism to fatty
acid oxidation [23]. The reason for this difference is
unclear; it could be due to species differences and to
differences in the relative levels of ERα versus ERβ in the
different species.
Hormone replacement therapy and the Women's Health
Initiative
Premenopausal women have reduced cardiovascular dis-
ease compared to men, but the incidence of cardiovascular
disease in women increases following menopause. These
observations led to the concept that hormone replacement
therapy might reduce cardiovascular disease. However, in
a large clinical trial, the WHI, HRT was not protective. To
better understand why the HRT did not show protection,
it is important to better understand the mechanism by
which estrogen is protective in animal models. Several
explanations have been proposed for the lack of protection
of HRT in the WHI in contrast to the protection observed
in premenopausal females. As reviewed elsewhere [61],
the dosage, duration, type of estrogen, and mode of ad-
ministration have been suggested to contribute to the lack
of protection. One popular hypothesis is the timing hy-
pothesis. The average age for initiating HRT in the WHI
was 63 years of age; thus, many women in the WHI were
10 years or more past menopause. It has been proposed
(see [61]) that the protective effects of estrogen are lost if
estrogen is absent for many years. For example, it is sug-
gested that changes might occur in the development of
atherosclerotic plaques, etc. and that this might not be
readily reversed with re-additon of estrogen. The WHI
data have been re-analyzed to evaluate the timing hypoth-
esis, and although some interpret the data as supporting
the timing hypothesis [61,62], others suggest that the re-
analyzed data do not support the hypothesis [63-65] and
others conclude that the data provided mixed support [66]
and that further study is needed. Some additional trials
have begun to more directly investigate the role of timing.
Another explanation for the lack of HRT protection in
the WHI is that age-related changes occur (with orwithout the continued presence of estrogen) and that
these changes impair the protection by estrogen. For ex-
ample, estrogen has been shown to upregulate nitric oxide
synthase, and at least some of the protection afforded by
estrogen is due to nitric oxide signaling. With age and oxi-
dative stress, nitric oxide synthase can become ‘uncoupled’
and produce superoxide instead of nitric oxide. If nitric
oxide synthase becomes uncoupled with age, this might
contribute to the lack of beneficial effects of HRT in older
women. In a variation on the timing hypothesis, it is inter-
esting to speculate that these age-related changes might
be slowed if estrogen is continuously present.
Differences in ischemia-reperfusion injury
A number of animal studies have found a sex difference
in cell death following ischemia and reperfusion. Fe-
males generally show less I/R injury compared to males
[37,67], although some studies do not observe reduced
injury in females [68]. This discrepancy appears to be
due to the extent of injury; a sex difference is usually
apparent with more severe I/R injury. For example, with
20 min of ischemia, Cross et al. observed no sex differ-
ence in I/R injury, but a sex difference was revealed if
contractility was increased prior to ischemia [69]. Estro-
gen appears to play a major role in this protection as
OVX females show increased I/R injury and protection
is restored with administration of estrogen [37]. Studies
have been done, using either ERα or ERβ knockout mice,
to investigate the relative role of ERα versus ERβ in
reducing I/R injury. The results have been mixed with
some studies suggesting a role for ERα [70-72] and
others suggesting a role for ERβ [23,24,41,73]. This dis-
crepancy is likely due to complex and non-overlapping
regulation of gene expression by ERα and ERβ. For
example, in vascular cells, ERα has been shown to be
important for protection from injury [74] whereas ERβ
regulates vasodilation [75]. Differences in the models of
I/R could result in differences in the relative levels of
ERα versus ERβ or differences in co-activators and
co-repressors, which, as discussed previously, can have
profound effects on the response.
Plasma membrane-localized estrogen receptors are also
important in cardioprotection. Treatment of a Langendorff
perfused heart with a GPR30 agonist, G-1, has suggested a
role for GPR30 in reducing I/R injury [7,76]. An estrogen
dendrimer conjugate (EDC), which is excluded from the
nucleus, has been shown to reduce vascular injury, sup-
porting a role for non-nuclear estrogen signaling [77]. The
precise role of these different receptors and whether there
is some redundancy will require further study.
Differences in hypertrophy and heart failure
Sex differences in the response to hypertrophy have been
reported. In response to transaortic constriction (TAC),
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males compared to males [78] and more slowly in OVX
females treated with estrogen compared to those treated
with vehicle [79]. Studies with mice lacking either ERα
or ERβ have generally suggested that ERβ is an import-
ant mediator of the protection as mice lacking ERβ de-
velop hypertrophy similar to that observed in mice lacking
estrogen [78]. There are also data showing that mice lack-
ing GPR30 exhibit increased blood pressure [80]. Chronic
treatment with the GPR30 activator G-1 has also been
shown to attenuate heart failure [81]. Although ERβ
appears to plan a key role in the sex differences in hyper-
trophy, the mechanism is likely to be more complicated
and is an area that deserves future investigation.
Conclusions
There are clear sex differences in cardiac function, and
these differences appear to be mediated at least in part
by the action of estrogen on several unique estrogen re-
ceptors. The effects of estrogen differ depending on the
relative levels of ERα and ERβ as well as on the comple-
ment of co-repressors and co-activators. The relative
level of GRP30 is also likely to influence the response of
the cell to estrogen. The relative levels of the estrogen
receptors and the co-regulators can change with disease,
age, and sex, thereby altering the response of the cell to
estrogen. In addition to the role of estrogen, other sex
hormones such as progesterone and testosterone and rela-
tive levels of the sex chromosomes are major contributors
to sex differences. Future studies will be needed to better
document how miRNA are regulated differently between
males and females and to better elucidate the interactions
between sex hormones and sex chromosomes. The inter-
action between signaling by ERα, ERβ, and GPR30 is also
an important topic for future studies. A mechanistic
understanding of the reasons for the discrepancy between
reduced cardiovascular disease in premenopausal women
and the lack of protection observed in the WHI is an
important topic for future studies.
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